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Abstract 
Although gender-based medicine is a relatively recent concept, it is now emerging as an 
important field of research, supported by the finding that many diseases manifest 
differently in men and women and therefore, might require a different treatment. 
Sex-related differences regarding the epidemiology, progression and treatment strategies of 
certain liver diseases have long been known, but most of the epidemiological and clinical 
trials still report results only about one sex, with consequent different rate of response and 
adverse reactions to treatment between men and women in clinical practice. 
This review reports the data found in the literature concerning the gender-related 
differences for the most representative hepatic diseases. 
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Introduction 
Gender-based research has expanded significantly in the last years, based on the premise 
that males and females show differences in the prevalence, pathophysiology and 
manifestations of several diseases. Such differences also manifest in the pharmacological 
treatment, which can differ in terms of required dose, administration timing and higher risk 
of adverse drug reaction in females compared to males [1].  
Despite most of the clinical trials have included mainly patients of one sex, there is much 
evidence that  certain liver diseases develop, manifest and are treated differently according 
to gender [2]. 
So far, the liver has also been described as a sexually dimorphic organ responsive to sex 
hormones by expressing androgen and estrogen receptors: this would explain to some 
extent the disparity found in gene expression pattern, immune response and xenobiotic 
metabolism between men and women [3, 4]. 
In this review we present the main gender-based differences reported in the literature with 
regard to the prevalence, prognosis and treatment of diverse liver diseases. 
1. Drug toǆicitǇ and the ͚drug-dose gender gap͛ 
Many studies have proven that women respond differently, and more often develop 
adverse reaction, to several drugs compared to men. The relative weight difference that 
exists between male and female sex, leading to a higher concentration and drug exposure in 
females, was considered to be a detrimental factor in order to explain this so called ͚drug-
dose gender-gap͛ [1], but it has so far been discounted. 
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Excluding behavioural or dosing differences, three mechanisms would explain the gender-
based differences seen in drug response and susceptibility to toxic effects: gender 
differences in pharmacokinetics, gender-specific hormonal effects or interaction with 
signalling molecules that can affect drug effect and safety and differences in aberrant 
immune response targeting the organs following drug exposure [5]. 
Gender-based differences that can influence drugs pharmacokinetics include variations in 
gastric acid secretion, gastrointestinal and renal blood flow, a different drug/plasma protein 
binding profile, the relative percentages of muscular and adipose tissue and physiologic and 
hormonal changes during the menstrual cycle [5, 6] (Figure 1).  
Gender-specific differences in gene expression or activity of drug metabolizing enzymes and 
transporters have been proved [7]. Males have higher glucuronidation rates, mainly via 
UDP-glucuronosyltransferases (UGT) activity, therefore greater paracetamol clearance than 
women [8]. Also, differences in major drug metabolising enzymes belonging to the 
cytochrome P450 family are clearly established: for instance,  CYP3A4 is more expressed in 
women [9]. 
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Figure 1. Major determinants of gender-based differences in liver toxicity and damage 
 
Abbreviations: ROS, reactive oxygen species; BMI, body mass index; GI, gastrointestinal; 
GFR, glomerular filtration rate; CYP, cytochrome P450 isoenzyme. 
2. Liver disease from toxic cause 
2.2 Drug-induced liver injury (DILI) 
Drug-induced hepatotoxicity is often the reason for the withdrawal of drugs from the 
market and the major cause of acute liver failure in western countries with a high 
percentage of cases requiring liver transplant [10]. Its annual incidence in the general 
population ranges between 14 and 19 events per 100.000 inhabitants, with almost one third 
developing jaundice [11, 12].  
All drug-induced adverse reactions can be classified into intrinsic or idiosyncratic adverse 
reactions [13]. Intrinsic adverse reactions are those usually caused by drugs that predictably 
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induce liver injury in a dose-dependent manner. Idiosyncratic adverse reactions are less 
related to dose, more rare and varied at presentation and tend to develop in susceptible 
individuals. 
With a few exceptions, the main being paracetamol-induced direct hepatotoxicity, most of 
drug-induced-liver-injury (DILI) cases in humans are considered to be idiosyncratic.  
Although idiosyncratic DILI is not directly related to drug dose, several data show that most 
of idiosyncratic cases do occur at high drug concentrations [14], implying therefore a less 
strict sense of the conventional dose-independency definition.  
The majority of DILI episodes are self-limited and resolve after cessation of the causative 
agent, although about 18% of patients will progress to chronic DILI [15], defined as 
continued injury six months after the initial diagnosis [16].  
Idiosyncratic DILI usually involves damage to hepatocytes with various degrees of necrosis 
and apoptosis with consequent hepatitis symptoms and biochemical alterations, while 
allergic drug-induced liver reactions are characterised by an IgE immune response and can 
be associated with systemic manifestations such as rash, fever and eosinophilia [10].   
In cholestatic type reactions, injury to bile duct cells and components is prevalent, leading to 
jaundice and pruritus and, in more severe cases, to vanishing bile duct syndrome [17]. Other 
possible types of DILI include granulomatous, steatohepatitis, autoimmune, fibrosis reaction 
and oncogenetic activation. 
From a histological perspective, acute and chronic hepatitic, acute and chronic cholestatic 
and mixed hepatitis-cholestatic patterns are the most common of the eighteen patterns 
identified by the Drug-Induced Liver Injury Network (DILIN) [18].  
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Drug properties possibly linked to DILI risk in humans are dose threshold, lipophilicity, 
formation of reactive metabolites, mitochondrial liability, inhibition of ATP-dependent bile 
salt export pump (BSEP) and other hepatobiliary transporters.  
It has been reported that females have about 1.5 fold greater risk of developing an adverse 
drug reaction compared to males [19]. This is mainly due to gender-based differences in 
pharmacokinetics and pharmacodynamics but also to differences in  immune response and 
inflammation corresponding to a higher level of hepatic pro-inflammatory cytokines, higher 
antibody production and more severe hepatitis in females compared to males [20]. Also, sex 
hormones may play a role, with estrogens reducing liver injury while progesterone 
contributing to liver damage, likely modulating inflammation and immune response, as seen 
in animal models   [21].  
In addition, a different susceptibility and response to toxicity in hepatocytes and 
cholangiocytes depending on sexual dimorphism (XX vs. XY), as showed in neurons and 
splenocytes, has been postulated [22, 23]. 
A female predominance of drug-induced hepatitis has been observed for several drugs while  
chronic liver injury, for instance due to azathioprine, has been seen mostly in men, although 
prevalence and incidence  slightly vary among countries
 [24]
. 
In a French population-based study, the incidence rates of adverse hepatic reactions 
induced by drugs were similar in males and females until the age of 50 years but then 
became twice as high in women as in men [11].  
The DILIN analysed 899 patients with DILI in a prospective cohort study in the US: 59% of 
patients were women and the most common agents implicated in short-latency DILI cases 
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were anti-infective agents (moxifloxacin, azithromycin, ciprofloxacin, rifampin, and 
levofloxacin). Agents more frequently implicated in long-latency DILI cases were 
minocycline, statins, amiodarone, mercaptopurine, atomoxetine, tamoxifen, oxaliplatin and 
interferoŶ β [15]. 
In another prospective study from Iceland involving 96 patients diagnosed with DILI, 56% 
were females and the most common involved drugs were amoxicillin/clavulanate, 
diclofenac, azathioprine, infliximab, nitrofurantoin [12].  
Antibiotic agents were also the more frequently associated with hepatotoxicity in a cohort 
of 461 patients with DILI registered in southern Spain [25]. In this cohort of patients, males 
represented the majority of idiosyncratic hepatotoxicity cases (52%), while almost all 
patients who developed drug-induced fulminant hepatic failure were females (89%) [25]. 
The Acute Liver Failure Study Group has demonstrated a female preponderance in acute 
liver failure due to either paracetamol (74%) [26] or idiosyncratic drug-induced adverse 
reactions (67%) [27].  
So far, this evidence supports that women are at increased overall risk for DILI and more 
likely than men to present with or progress to acute/fulminant liver failure.  
2.2 Alcoholic liver disease (ALD) 
Alcohol abuse is a well-known risk factor for progressive liver disease leading to cirrhosis 
and end-stage liver disease [28].  
 The prevalence of alcohol drinking varies among countries and according to gender, with 
rates from 3 to 94% for women and from 37 to 97 % for males [29]. 
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In a recent systematic review on sex differences in alcohol use, women were found to 
consume less alcohol than men, to drink less frequently, and to be less likely to become 
hazardous drinkers [30].  
Alcohol-induced liver injury encompasses mechanisms such as generation of reactive 
oxygen species (ROS) from hepatic alcohol metabolism, oxidative stress, loss of protective 
liver enzymes and transporters and release of pro-inflammatory cytokines, also sustained by 
the immune activation in response to increased level of gut-derived endotoxin induced by 
ethanol exposure [31].  
It has been shown that risk of progression to alcohol-induced cirrhosis increases with a daily 
intake of alcohol higher than 30 g/day [32].  
Based on the epidemiological evidence of a threshold effect of alcohol, a limit of 16 g/day in 
women and 24 g/day in men  has been suggested in order to prevent liver damage [33, 34]. 
However, data suggest that even a lower quantity of alcohol may be toxic in women, 
therefore a threshold of no more than 60 g  per week should be suggested [35]. 
Several studies have proved that female sex is more susceptible to the toxic effects of 
alcohol: women develop ALD and progress to alcoholic cirrhosis after a shorter period of 
heavy drinking compared to men and at a lower level of daily drinking [36]. Results from a 
systemic meta-analysis on alcohol as a risk factor for liver cirrhosis and related mortality, 
showed that women had higher relative risk than men for development of cirrhosis and 
mortality for the same amount of drinking [37]. 
One of the explanations for the lower alcohol toxic threshold seen in females is the lower 
level of gastric alcohol dehydrogenase compared to males. This would lead to lesser gastric 
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oxidation of ethanol and therefore an increment in its bioavailability [38]. A different 
composition in total body water and fat may influence alcohol distribution [5]. 
In addition, females have a higher inflammatory activation in response to increased gut-
derived endotoxin caused by alcohol exposure compared to males: estrogen seems to have 
major influence on the susceptibility of Kupffer cells to gut-derived lipopolysaccharide and 
this would result in increased pro-inflammatory cytokine production [39, 40], worse 
inflammation and higher risk of liver disease progression. 
3. Autoimmune liver disease 
3.1 Autoimmune Hepatitis 
Autoimmune hepatitis (AIH) is a disease of the hepatic p renchyma defined by progressive 
inflammatory destruction, circulating autoantibodies, hypergammaglobulinaemia and 
interface hepatitis on histology [41].  
AIH is highly prevalent in female sex, with women representing the 70–90% of affected 
patients, with a double peak distribution in terms of age at diagnosis/first presentation 
(between 10 and 30 years or during late middle age) [42]. Prednisone alone or in 
combination with azathioprine is the established treatment of AIH [43]. 
Histocompatibility leukocyte antigens (HLA) DR3 and HLA DR4 are susceptibility factors for 
type 1 AIH in Caucasian Northern European and North American patients [44, 45], while HLA 
DR4 is predominant in Japanese patients [46]. HLA DR4 occurs more commonly in women 
than men with type 1 AIH and it has been associated with concurrent immune diseases and 
remission during corticosteroid therapy, while HLA DR3 has been associated with early age 
onset and treatment failure [47, 48]. 
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Whether disease expression and outcome differ according to gender and whether HLA DR3 
and DR4 have a synergism with gender is poorly understood, and available studies show 
discrepant findings.  
Czaja et al analysed a cohort of 185 well-defined AIH patients and did not find any 
significant gender-based difference in terms of response to steroid treatment, whereas HLA 
haplotype (DR3 or DR4) was the only predictor of  treatment failure and risk of progression 
to liver failure/ liver transplant in women, with HLA DR3 being associated with failed 
treatment response in both genders [49].  
In another study involving a highly-selected European cohort of 238 patients with AIH, men 
appeared to have better long-term survival and outcome than their female counterparts 
independently of HLA allotype [50]. 
In a Japanese study evaluating clinical features of AIH male patients, the frequency of 
normalization of the serum ALT level within six months after the beginning of corticosteroid 
treatment was significantly lower in men (73%) as compared with women (93%) [51]. 
Nonetheless, the number of male patients was limited and the statistical difference in 
response was marginal. In addition, 36 patients were treated with ursodeoxycholic acid or a 
combination of lower doses of prednisolone and UDCA; the role of UDCA on the outcome of 
patients with AIH is at least uncertain [52].  
It is still not clear whether gender (particularly female sex) confers only a susceptibility to 
the development of AIH or it has an influence on drug response, and if so, by itself or by 
modulation of the immune response. Indeed, it has been postulated that  sex hormones 
may play a role  in systemic immunologic response by influencing maturation of adaptive 
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lymphocytes, antigen presentation and cytokine secretion after binding to hormone 
receptors expressed by immune cells[53].  
3.2 Primary Biliary Cholangitis 
Primary Biliary Cholangitis (PBC) is an autoimmune liver disease, consisting of a chronic non-
suppurative destructive cholangitis which affects women ten times more often than men. 
Ursodeoxycholic acid (UDCA) is the only recognised medical treatment at the moment, with 
liver transplantation as a final option for those cases that progress to  end-stage liver 
disease [54].  
PBC is highly variable in terms of clinical impact on patients, and one of the main aspects of 
this is the response to UDCA treatment: a significant subgroup of patients has a suboptimal 
biochemical response to UDCA thus predicting a poor outcome [55, 56] although it has been 
suggested that the UCDA ͞respoŶse͟ ŵight aĐtually represeŶt spoŶtaŶeous ďioĐheŵiĐal 
improvement unrelated to the medication [57]. 
Whether the disease phenotype is the same in PBC male and female patients is still unclear 
and not studied in depth, mainly because of the rarity of male patients and the difficulty in 
developing adequately powered cohorts. So far, satisfactory reasons to explain the rarity of 
PBC in males are still lacking.  
 Clinically speaking, women tend to present with pruritus as first symptom more often than 
males [58]. 
A recent study from the United Kingdom Primary Biliary Cholangitis (UK-PBC) consortium 
investigated the impact of gender in predicting prognosis in PBC in a cohort including 2353 
non-transplanted PBC patients [59]. Men presented at an older age and with a more severe 
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disease and male sex was an independent risk factor for non-response to UDCA on 
multivariate analysis. Also, female sex revealed a clear age-related difference in response to 
UDCA: women presenting younger than the age of 45 (the age of equivalent likelihood of 
response between the groups) were significantly less likely to respond to UDCA than either 
men or older women at presentation, with age again being an independent predictor of 
UDCA response on multivariate analysis.  
The inclusion of patients from every PBC centre in the United Kingdom and the size of the 
cohort make these data very useful for clinical practice. Moreover, the age and gender 
association with non-response could help to tailor novel therapies, e.g. estrogen-targeting 
therapies might have a role in non-UDCA-responding young female patients.  
3.3 Primary Sclerosing Cholangitis 
Primary sclerosing cholangitis (PSC) is a chronic condition in which inflammation of the bile 
ducts,  both intrahepatic and extrahepatic, lead to cholestasis and progressive hepatic 
fibrosis [60].  
The most accredited pathophysiological theory is the activation of a persistent immune-
mediated damage to cholangiocytes following the exposure to infective or toxic agents, with 
progressive destructions of bile ducts and chronic cholestasis [61]. 
PSC cannot be considered as a classical autoimmune disease, as it occurs with male 
predominance (M:F ratio 7:3) and lacks characteristic response to immunosuppressants 
[62]. 
At this time, there is no established medical treatment for patients with PSC and elective 
liver transplant often represents the treatment of choice in advanced stages [63]. 
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4. Viral Hepatitis 
4.1 Hepatitis C 
The number of hepatitis C virus (HCV) cases is estimated to be about 160 million worldwide, 
with most of affected individuals being unaware [64]. The incidence, prevalence and 
male/female ratio of HCV infection and chronic hepatitis C (CHC) vary extremely, depending 
on the geographical area and likely reflecting cultural, behavioural and social differences 
influencing the risk of exposure, the timing of the first diagnosis and access to treatment 
[65].  
The long-term prognosis of such infection is highly variable, and ranges from minimal 
histological changes to cirrhosis with potential development of hepatocellular carcinoma 
(HCC).  
The proportion of subjects that spontaneously clear the virus after the infection ranges from 
10 to 26%, with a high rate of chronicity expected [66, 67]. Female gender has been 
associated with higher rates of spontaneous viral clearance, symptomatic disease with 
jaundice and genetic polymorphisms of interleukin-28B (IL28B, also named IFN lambda-3, 
IFNL3) [68, 69].  
A large study on 632 patients with acute HCV from different countries showed that 
spontaneous viral clearance was favourable predicted by IL28B CC genotype, HCV genotype 
1 and female sex [70]. Also, the effect of IL28B CC genotype on clearance was greater, even 
if not statistically significant, among females than males, in consistency with a possible 
synergistic effect between IL28B CC genotype and female sex demonstrated by previous 
findings [71]. The potential interaction between female gender and Il28B polymorphism 
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might be explained by a mechanism involving the stimulation of toll like receptor 7 (TLR7), a 
receptor involved in recognition of viral products and activation of innate immunity, and a 
subsequent increase in IFN-α aŶd IFN-λ respoŶses. 
The association between female gender and spontaneous viral clearance may also be 
partially explained by the sex-based differences in immunity, likely due to the direct 
influence of sexual hormones on immunological cells [72, 73].  
Another study demonstrated a gender-dependent role for certain polymorphisms of CTLA4, 
an inhibitory T-cell receptor expressed on activated regulatory T-lymphocytes, in 
spontaneous or interferon-alpha-induced resolution of chronic hepatitis C virus infection 
[74], implying that gender-based differences in immunity response could influence the 
response to interferon treatment in patients with CHC. 
Males with CHC have a two-fold greater progression rate to fibrosis compared with females, 
independently from alcohol intake [75]. The frequency of the IL-10 promoter GG genotype, 
associated to higher levels of interleukin 10, was tested in patients with HCV infection: 
female patients, who had an increased prevalence of such genotype, tended to develop CHC 
but had a lower risk of progression to cirrhosis [76].  
Also, in an Italian gender-oriented analysis of CHC patients treated with pegylated-
interferon and ribavirin, different predictive factors for SVR according to gender were found: 
SVR was independently associated with younger age and IL28B CC genotype in females, 
while absence of visceral obesity, HCV-RNA lower than 400 000 IU/mL and IL28B CC 
genotype were independently associated with SVR in males [77].  
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Female sex was associated to a higher incidence of adverse events (i.e. anaemia) and the 
need for dose modification in retrospective studies on treatment of HCV with pegylated-
interferon and ribavirin, but had the same SVR rate if compared with male sex [78]. 
As for the new direct acting antiviral (DAA) treatments, the SVR is usually reached in over 
90% patients with HCV, independently of virus genotype, patient sex and liver disease stage, 
thus offering an unprecedented opportunity to cure hepatitis C virus (HCV) infection [79-
81].  
4.2 Hepatitis B  
Hepatitis B virus (HBV) is an important cause of acute and chronic liver disease globally. 
Despite an  encouraging decline in its incidence, likely attributable to effective vaccination 
programs especially in western countries, it is estimated that 240 million persons worldwide 
have chronic hepatitis B (CHB) with a geographically variable prevalence [82].  
Chronic HBV infection is associated with hepatocellular  necroinflammation and progression 
to hepatic fibrosis, and it is an independent recognised risk factor for hepatocellular 
carcinoma (HCC) development even in the absence of liver fibrosis [83].  
A higher male prevalence among CHB carriers is established, as well as a gender-based 
disparity in HBV clearance, which is higher in HBV-infected females. 
Furthermore, male sex is an independent predictor of liver disease severity among chronic 
HBsAg carriers, with males having a more rapid progression of liver disease, higher 
morbidity, HCC incidence and mortality if compared to females [84-86]. 
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 Both control of the HBV-induced liver damage and immune clearance of HBV antigens are 
usually more quickly achieved in women, likely for the different regulation of immune cells 
from male and female sex hormones,  as seen for HCV infection. 
HBV is considered to be a sex hormone-responsive virus, differently regulated by hepatic 
androgen or hepatic estrogen axis. Indeed, it has been seen that, once stimulated, the 
androgen receptor (AR) actively binds to the androgen responsive elements (AREs) within 
HBV enhancer 1 leading to a subsequent increase of overall HBV mRNAs production [87]. On 
the other side, it has recently been provided that estrogen binding to hepatic estrogen 
reĐeptor α ;ERαͿ reduĐes oǀerall HBV ŵRNA leǀels ďy suppressiŶg the activity of viral 
enhancer 1 [88]. Moreoǀer, stiŵulated ERα passiǀely represses HBV traŶsĐriptioŶ by 
iŶteraĐtiŶg ǁith hepatoĐyte ŶuĐlear faĐtor ϰα ;HNF-ϰαͿ aŶd preǀeŶtiŶg its ďiŶdiŶg to ǀiral 
enhancer 1 [89].  
The greater rate of hepatic fibrosis progression seen in men may be due to a lower 
production of estradiol, an estrogen hormone but also an endogenous antioxidant that 
reduces redox hepatocellular apoptosis and hepatic stellate cells (HSC) activation  by 
decreasing reactive oxygen species generation, thus suppressing hepatic fibrosis in animal 
models [90]. 
5. Metabolic liver disease 
5.1 Hereditary Hemochromatosis (HH) 
Hemochromatosis is a clinical syndrome caused by the toxic effects of excessive iron 
deposition in parenchymatous organs, nowadays recognised as due to partial or total loss of 
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activity of hepcidin, a liver-synthetized  hormone that prevents unneeded iron from 
entering the bloodstream by regulating its absorption [91]. 
 There are different types of hereditary hemochromatosis (HH): type 1 or classic HH, type 2 
or juvenile hemochromatosis, type 3 and type 4 or ferroportin disease [92, 93].  Type 1 HH,  
by far the most common form, is highly prevalent in the Caucasian population and  mainly 
caused by the homozygous mutation C282Y or by compound heterozygous mutations 
C282Y/H63D of the HFE gene [94]. The HFE gene encodes for a protein involved in the 
signalling pathway of iron status to hepcidin [95] and the loss of HFE function leads to 
inappropriately low hepcidin levels and iron overload [96]. 
Type 1 HH is typically an adult-onset disease with incomplete penetrance and genetic 
testing is  usually recommended for those individuals who have iron overload or a family 
history positive for HFE-associated HH [97]. Therefore, many cases of HH are diagnosed 
before the onset of clinical symptoms.  
Symptoms of HH usually appear in the fifth decade of age and include weakness, 
hepatomegaly, darkened skin and joint pain and overall the clinical severity is mild. If 
untreated, affected patients are at high risk of heart disease, endocrine dysfunctions  and 
liver cirrhosis [98]. 
 HH is not a gender-specific disease, but affected males tend to present symptoms earlier 
than females and this can be explained by the protective effect of the menstrual cycle in 
women.  Male patients with hemochromatosis tend to have higher ferritin levels, 
accumulate more iron and have a higher incidence of liver injury and progression to fibrosis, 
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requiring treatment with phlebotomy to be started earlier from the time of the diagnosis,  if 
compared with female subjects [99]. 
Also, symptoms of hypogonadism can be more evident in men, including erectile 
dysfunction, loss of secondary sexual characters, and infertility [100].  
5.2 Non-alcoholic fatty liver disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) is nowadays the most common cause of deranged 
hepatic function tests in western countries [101]. Its prevalence is widely variable and 
reaches 20-30% in Europe, Japan and US [102]. NAFLD is generally associated with obesity, 
insulin resistance and visceral adiposity, and it is considered to be the hepatic manifestation 
of the Metabolic Syndrome (MetS) [103].  
Histologically, NAFLD  extends from simple steatosis to steatohepatitis, fibrosis and cirrhosis  
and a prompt diagnosis, particularly of steatohepatitis and fibrosis at an early stage, is 
important in order to identify those patients who should undergo a stricter follow-up, 
interventions aiming at weight reduction, treatment of the other components of the 
metabolic syndrome and inclusion in trials for new therapeutic strategies [104].  
There are conflicting data in the literature about gender-based difference in NAFLD 
prevalence and prognosis. Despite being initially considered a female disease [105],  recent 
cross-sectional studies have shown that NAFLD is as common in men as in women [106]. 
Others have reported a higher prevalence of advanced disease among women, and 
therefore identified female sex as a risk factor for liver disease progression in NAFLD [107]. 
A recent review on the prevalence, gender and ethnic variations and prognosis of NAFLD in 
the Japanese population, pointed out that among younger patients both NAFLD and NASH 
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are more common in men while after 60 years of age, the prevalence of NASH is higher in 
women [108]. This may imply a protective role of endogenous estrogens in NASH, as seen 
for other liver diseases, against oxidative stress damage. Furthermore, estrogens promote 
accumulation of fat in the gluteo-femoral region
 
and, conversely, their loss during 
menopause is associated with an increase in central fat and visceral adipose tissue, both 
recognised as negative predictive factors for development and progression of NAFLD [109]. 
Another cross-sectional study involving 1170 community-based Australian adolescents 
showed that females had a significantly higher prevalence of NAFLD (16.3% versus 10.1%) 
and central obesity (33.2% versus 9.9%) while male phenotype of NAFLD was associated 
with more adverse metabolic features and a greater visceral adiposity [110]. These data 
suggest that more aggressive strategies should be offered to men of all ages with NAFLD, in 
order to address the higher rates of deranged behavioural habits and concomitant 
metabolic diseases, and to peri /post-menopausal women with NAFLD, who are at high risk 
of disease progression and cardiovascular comorbidities after the loss of estrogen protective 
effect.  
Definitive data are lacking, but a possible role for estrogenic treatment in postmenopausal 
women with NAFLD is emerging, also supported by the improvement of liver function tests 
seen in post-menopausal women taking estrogenic replacement therapy and by the 
observed association of NAFLD with the anti-estrogen tamoxifen [111, 112].  
6. Vascular liver disease 
Vascular liver disease encompasses a spectrum of diseases like Budd-Chiari syndrome (BCS), 
portal vein thrombosis, idiopathic non-cirrhotic portal hypertension, sinusoidal obstruction 
syndrome and hereditary haemorrhagic telangiectasia.  
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BCS is a rare disorder featured by venous flow obstruction at the suprahepatic level, usually 
caused by a combination of thrombogenic conditions and triggering factors. 
Epidemiologically, BCS is overall more common in males compared to females (1.5:1), with a 
distinction linked to the variant: isolated hepatic vein thrombosis, more commonly seen in 
Western countries, has a higher female prevalence, while combined hepatic-inferior cava 
vein thrombosis is more commonly seen in Eastern male patients[113, 114]. Females have 
higher rates of acute presentation of the disease and a greater probability to be managed by 
anticoagulation only.  
The management remains similar in non-pregnant women and men, except for oral 
contraceptive (OC) therapy, which is a well-recognised  additional risk factor for BCS in 
women that therefore needs to be investigated and stopped [115]. There is no difference in 
the recommended level of anticoagulation and interventional radiological procedures 
among both genders, with a risk of bleeding on anticoagulation that appears to be similar 
for both genders [116].  
According to a recent systematic review and meta-analysis, pregnancy-related BCS has a 
prevalence that varies from  0 to 21.5% (pooled prevalence between 6.7 and 7.3 %), and it 
can present with acute fulminant liver failure due to occlusion of all three hepatic veins 
during pregnancy or puerperium [117]. Particularly, women with protein S deficiency seem 
at higher risk for developing BCS during pregnancy [118].  
Hereditary haemorrhagic telangiectasia is a rare genetic condition that affects the liver by 
the development of venous malformations (VMs). Previous data show a strong and 
significant predominance of hepatic VMs in females who have HHT, both for asymptomatic 
and symptomatic lesions, with a male : female ratio varying from 1:2 to 1:4.5 [119].  
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OC therapy is an acquired risk factor for other vascular disorders in women: particularly, 
hepatic sinusoidal dilatation and hepatic peliosis are classic complications of long-term use 
of OCs [120]. 
7. Neoplasms of the liver 
7.1 Benign Hepatic Lesions 
 Several benign liver tumours are more common in women. Benign liver lesions that 
predominantly occur in women include cavernous haemangioma, focal nodular hyperplasia 
(FNH), hepatic adenoma, biliary cystadenoma and solitary hepatic cysts. Estrogens are 
associated to benign liver tumours, likely for an increase of hormonal receptors expression 
and estrogens-stimulated hepatocellular replication in such lesions, although the exact 
mechanisms are still unclear. 
Hemangioma is the most common, with an estimated prevalence of 5% in imaging series 
and of 20% in autopsy series and a variable female to male gender ratio (between 1.2:1 and 
6:1) [121]. It is usually diagnosed incidentally because asymptomatic, and it is managed 
conservatively, with no gender disparity in most cases. Oral contraceptives and pregnancy 
are usually not contraindicated, although rare cases of development of Kasabach–Merritt 
syndrome, a potentially life-threatening coagulopathy characterized by enlarging 
hemangioma and thrombocytopenia, usually associated with kaposiform 
hemangioendothelioma (KHE), tufted angiomas and rarely with congenital hemangiomas, 
have been described in pregnant women with liver hemangiomas larger than 5 cm [119].  
FNH has a prevalence ranging between 0.4% and 3%, with a strong female preponderance 
(90 % of cases) [122]. However, there is no discrepancy in the histological features, the 
natural history and the management of FNH according to gender. For a typical FNH lesion, 
follow-up is not necessary unless there is underlying vascular liver disease, and surgical 
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treatment is usually pursued in exceptional cases (pedunculated, expanding, exophytic 
lesions). There is no indication for discontinuing OCs and follow-up during pregnancy is not 
necessary [121]. 
Adenomas are monoclonal tumours that are defined as HNF1-α type, inflammatory type, 
Beta-catenin type and unclassified. Females have mainly the first two types of adenoma, 
usually associated with a better prognosis.  
Hepatic adenomas were rarely reported before the advent of OCs and multiple studies 
carried out thereafter have confirmed an association between the development of hepatic 
adenomas with the dose and duration of hormonal therapy, with a higher risk of 
development in women over the age of 30 years who have been using OCs for longer than 
25 months, likely due to the effect of estrogens on hepatocytes [123-125]. The annual 
incidence is approximately 1 per million in women who have never used OCs compared with 
30 to 40 per million in long-term users [126]. Additionally, adenomas are more numerous, 
larger, and more likely to bleed in patients who take OCs.  Regression of adenomas has been 
observed after discontinuation of OCs with recurrence during readministration or pregnancy 
[127-129]. Therefore, all females are advocated to stop using OCs after the diagnosis of 
adenoma.  
In male patients all adenomas are to be resected, while in females only those larger than 5 
cm or proved to be enlarging on the sequential scan are to be resected.  
Emerging understanding of the FNH and adenomas pathogenesis points out that males are 
more predisposed to develop adenomas with beta-catenin activation, while females appear 
to have the inactivation of a gene involved in estrogen metabolism (CYP1B1) and a 
consequent higher rate of the HNF1-α suďtype of adeŶoŵas [130] . Inactivating mutations 
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of HNF1-α ;a huŵaŶ tuŵour suppressor geŶeͿ ǁas fouŶd iŶ ϯϱ% to ϱ0% of hepatiĐ 
adenomas [131]. 
7.2 Hepatocellular carcinoma (HCC) 
Hepatocellular carcinoma (HCC) is the third most common cause of death from cancer 
worldwide and it is notably more prevalent in males in most of the published studies, with 
reported male to female ratios ranging from 2:1 to 8:1 [132].  
The reasons for sex differences in the incidence of HCC are still unclear. Considering that this 
gender disparity is quite significant for pre-menopausal women, a protective role of 
estrogen towards HCC development has been postulated. Furthermore, studies have 
demonstrated that androgen/androgen-receptor (AR) signalling has an important role in 
cancer initiation [133, 134] while it seems to suppress metastasis of HCC, exerting a 
suppressive effect on the progression of late-stage HCC [135]. Nevertheless, the association 
between increasing levels of testosterone or anabolic hormones and development of HCC 
remains controversial [136-139]. 
Women are usually diagnosed with HCC at a significantly older age than men and are also 
more likely to be diagnosed by screening methods at an earlier, asymptomatic stage of 
disease, with fewer and smaller tumours [140, 141]. However, when diagnosed after 
symptomatic presentation they tend to have a diffuse infiltrating variety of HCC and a more 
advanced stage of the disease [141-145]. 
Overall, females are either equal or more likely to undergo therapeutic curative procedures, 
including surgical resection (lobar/segmental), transplantation or radiofrequency ablation 
[141, 142, 146].  
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Even when compared to males undergoing surgical resection, female patients  tend to have 
higher tumour encapsulation, lower tumour microsatellites, lower liver invasion,  lower 
incidence of tumour recurrence [147] and more favourable actuarial survival.  
Males are more likely to undergo non-curative systemic therapy and male sex is considered 
to be an independent risk factor for poor outcome of HCC [141, 142].  
Sorafenib is a multikinase inhibitor approved for treatment of patients with advanced 
hepatocellular carcinoma who have compensated liver function (class Child-Pugh A) but are 
not candidates for potentially curative treatment or trans-arterial chemoembolization [148]. 
In studies on sorafenib pharmacokinetics and pharmacodynamics, gender was the sole 
parameter independently associated with sorafenib exposure, with a greater absolute AUC 
in females than in males [149] and a likely synergism between sorafenib and estrogens in 
terms of anti-HCC activity [150]. Female gender is a better prognostic factor either in 
resectable either in unresectable HCC, with an increased overall survival [145, 151]. 
 
Table 1. Gender-based differences in liver diseases 
Liver disease M : F Female Male 
 
 
DILI 
1  1.5 - More frequent 
presentation 
with/progression to 
ALF 
- Hepatitis type 
Higher incidence 
of chronic liver 
injury type  
 
 
ALD 
1.5-2 1 - Lower alcohol toxic 
threshold 
- Faster progression 
to liver fibrosis 
 
 
AIH 
1  7-9 Different response 
to therapy? 
 
 
PBC 
1  10 Pruritus as first 
symptom 
-Presentation at 
an older age with 
more severe 
disease  
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- Non-response to 
UDCA  
PSC 7 3   
 
 
 
 
 
 
HCV 
Variable 
M > F 
 
- Higher rate of 
spontaneous viral 
clearance 
- Presentation at a 
younger age, with 
jaundice 
- Higher prevalence 
of IL28BCC 
polymorphism 
- Higher incidence of 
adverse events, i.e. 
anaemia, on PEG-
IFN/RBV 
Greater 
progression rate to 
liver fibrosis 
 
 
HBV 
Variable 
M > F 
Quicker control of 
HBV-induced liver 
damage  
- Lower HBV 
clearance 
- Rapid 
progression of 
liver disease 
- Higher morbidity, 
HCC incidence and 
mortality 
 
HH 
M   ̴ F  - Earlier 
presentation 
- Higher ferritin 
- Higher incidence 
of liver injury 
- More evident 
hypogonadism  
 
NAFLD 
Contrasting 
data 
Increased incidence 
after menopause  
 
BENIGN 
VASCULAR 
LESIONS 
BCS 
 
 
 
 
 
1.5  
 
 
 
 
 
 
 
1 - Isolated hepatic 
vein thrombosis 
- OCP-associated 
risk 
- Higher rates of 
acute presentation 
- More often 
managed by 
anticoagulation only 
- Combined 
hepatic-inferior 
cava veins 
thrombosis 
 
 HHT 1 2-4.5   
BENIGN 
LESIONS 
Adenoma 
 
 
1 
 
10 - Higher prevalence 
of HNF1-α suďtype  
- Strong association 
Higher prevalence 
of Beta-catenin 
activation 
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 with OCPs 
 FNH 1  9   
 
HCC 
 
2-8  
 
1 
- Better response to 
Sorafenib 
- Increased overall 
survival 
Higher risk  for 
poor outcome of 
HCC 
 
Abbreviations: DILI, drug-induced liver disease; ALF, acute liver failure ; ALD, alcoholic liver 
disease; AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; UDCA, u ursodeoxycholic 
acid; PSC, primary sclerosing cholangitis; HCV, hepatitis  C virus; PEG-IFN, pegylated 
interferon; RBV, ribavirin;  HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HH, 
hereditary hemochromatosis; NAFLD, non-alcoholic liver disease;  BCS, Budd-Chiari 
syndrome; OCP, oral contraceptive pill; HHT, hereditary haemorrhagic telangiectasia; HMG, 
hemangioma; FNH, focal nodular hyperplasia. 
 
8. Advanced liver disease and cirrhosis 
Male patients with chronic liver disease tend to have a faster progression of liver fibrosis 
compared to women except for ALD [152] patients (Table 1).  
Cirrhotic patients are more often males with underlying viral and/or alcoholic liver disease  
[153-155], while women represent less than 40% of all patients with cirrhosis in the 
Western countries, with autoimmune hepatitis and primary biliary cirrhosis as main 
underlying aetiology [156, 157].  
Such favourable effect of the female sex relies on many factors, as already mentioned in the 
sections dedicated to the specific liver diseases: a lower risk of iron overload, a lower 
prevalence of viral infections and overweight, a lower alcohol and tobacco consumption and 
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a positive influence of estrogens and/or estrogen receptors pathways on fibrogenesis, the 
latter explaining the gradual increase in morbidity after the onset of menopause. 
The incidence of decompensation events, such as variceal haemorrhage, development of 
hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis and their 
management is usually similar in both sexes and related to the liver disease stage, but some 
differences in natural history, manifestations and mortality risk may encourage a gender-
based approach to counselling and follow-up. 
Hypogonadism is a common finding in patients with liver cirrhosis. Altered albumin 
synthesis secondary to malnutrition, reduced clearance of sex hormones, systemic toxaemia 
and altered antero-pituitary hormone secretion (sometimes aggravated by metabolic 
damage from toxic causes as in ALD or HH) are the main culprits. 
Clinical signs related with hypogonadism in cirrhotic men (abnormal distribution of fat and 
gynaecomastia, testicular and prostatic atrophy, decreased libido, erectile dysfunction and 
infertility[158, 159]) are mainly caused by low serum testosterone and high estrogen levels 
and often exacerbated by the introduction of spironolactone [160, 161].  Testosterone 
deficiency has been identified as an independent prognostic marker in cirrhosis [162].  
Typical signs of hypogonadism in cirrhotic women are loss of secondary sexual 
characteristics, anovulation, amenorrhoea and infertility due to lower levels of total 
testosterone and higher levels of prolactin and delta-4-androstenedione [161, 163].  In the 
presence of compensated cirrhosis and mild portal hypertension, regular menstrual circle is 
preserved and hormonal replacement therapy is not contraindicated.  
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Pregnancy is a rare event in patients with cirrhosis. Despite the exact incidence is unknown, 
maternal mortality and pregnancy outcome have likely improved along with advancements 
in the treatment of specific liver diseases and in the management of portal hypertension 
and variceal haemorrhage [164]. Further studies are required of specific treatment with 
gonadal hormone replacement in patients with liver cirrhosis. 
Hypogonadism can also worsen clinical manifestations of advanced liver disease such as 
sarcopenia and bone disease.  
Malnutrition is one of the most common complications in cirrhosis and it leads, in the 
majority of cases, to a chronic catabolic state with consumption of amino acids and 
sarcopenia [165] . Male sex has been found to be a predictor for sarcopenia and this could 
be linked to the abundance of fat stores in women, even in advanced stages of liver disease, 
and to a different, sex hormone-dependant, pattern of skeletal muscle turnover [166] . 
Patients with cirrhosis should be screened for osteoporosis irrespective of gender. 
Nevertheless, since female sex, advanced age, chronic cholestasis and long-term use of 
steroid therapy are independent risk factors for osteoporosis, the prevalence of 
osteoporosis tends to be higher in cirrhotic postmenopausal patients [167, 168]. 
Bisphosphonates are the agents of choice for the treatment of hepatic osteoporosis, and 
hormone replacement therapy can be an option for post-menopausal cirrhotic females 
[168]. 
Porto-pulmonary hypertension (PPHTN), a possible complication of liver cirrhosis, develops 
more often in female patients compared to males, however the treatment is the same [169, 
170]. 
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Overall, males are two-fold more likely of being hospitalized and dying of liver cirrhosis than 
females [155, 171].  
Women have lower rate of progression to end-stage liver disease and better long-term post-
transplant survival, although female sex seemed to be associated to a worst outcome in 
case of HCV reactivation after liver transplant , at least in the pre-DAAs era [172]. Female 
sex is also a predictor of mortality on liver transplant waiting list and the disparity in the 
female/male liver transplant rates has particularly increased after the introduction of the 
Model for the End-stage Liver Disease (MELD) Score to assess and stratify patients with 
advanced liver disease [173] [174]. This could be due either to the reduced muscle mass in 
women, therefore lower average levels of creatinine (one of the components of the MELD 
Score) either to the difficulty of finding an appropriately sized graft. 
Conclusions 
Gender variations in prevalence, incidence, manifestations and outcomes prevail in common 
liver diseases, and such differences are important to identify as they influence the likelihood 
of a given diagnosis for a patient, the potential for progression of the liver disease and the 
preventive as well the therapeutic strategies.  
During the last decades, basic scientific and clinical research has been proved to be gender 
unbalanced, with female subjects traditionally underrepresented.  
Therefore, a renewed attention on a more gender-specific approach to hepatology and 
medicine in general is required and the efforts of the scientific community should be 
addressed towards a better understanding of the mechanisms underlying such differences, 
likely centred on differing behavioural, hormonal and immune factors. 
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